Terumo (OTCMKTS:TRUMY) Upgraded by Nomura to “Hold” Rating

Terumo (OTCMKTS:TRUMY) was upgraded by research analysts at Nomura to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

Terumo Stock Up 2.7%

TRUMY stock opened at $13.19 on Tuesday. The business’s 50-day moving average price is $13.84 and its 200-day moving average price is $15.64. The stock has a market cap of $19.46 billion, a P/E ratio of 22.74 and a beta of 0.74. The company has a quick ratio of 1.46, a current ratio of 2.51 and a debt-to-equity ratio of 0.07. Terumo has a twelve month low of $12.15 and a twelve month high of $20.12.

Terumo (OTCMKTS:TRUMY) last released its earnings results on Friday, February 13th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Terumo had a return on equity of 9.13% and a net margin of 11.74%.The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.82 billion.

Terumo Company Profile

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.